Axsome Therapeutics, Inc. (AXSM) Q2 FY25 Earnings Call

Q2 FY25 results, source: company transcript and SEC filings
QuarterQ2 FY25
Call date2025-08-04
Length55 minutes
EPS$-0.92
Revenue$150.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26 · Q4 FY25

All AXSM earnings · Back to AXSM overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.